Goldman Sachs Group Inc. cut its stake in Kindred Biosciences, Inc. (NASDAQ:KIN) by 30.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,510 shares of the biopharmaceutical company’s stock after selling 6,826 shares during the period. Goldman Sachs Group Inc. owned about 0.06% of Kindred Biosciences worth $133,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in KIN. Nationwide Fund Advisors purchased a new position in Kindred Biosciences in the second quarter valued at $100,000. JPMorgan Chase & Co. purchased a new position in Kindred Biosciences in the second quarter valued at $119,000. Trexquant Investment LP purchased a new position in Kindred Biosciences in the second quarter valued at $120,000. OxFORD Asset Management LLP purchased a new position in Kindred Biosciences in the second quarter valued at $128,000. Finally, State of Wisconsin Investment Board purchased a new position in Kindred Biosciences in the second quarter valued at $129,000. Hedge funds and other institutional investors own 61.77% of the company’s stock.

A number of research firms have weighed in on KIN. Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research note on Wednesday, September 27th. B. Riley restated a “buy” rating and issued a $11.00 price target on shares of Kindred Biosciences in a research note on Monday. Finally, HC Wainwright began coverage on Kindred Biosciences in a research note on Friday, November 17th. They issued a “buy” rating and a $9.50 price target on the stock. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Kindred Biosciences presently has a consensus rating of “Buy” and a consensus price target of $9.54.

Shares of Kindred Biosciences, Inc. (NASDAQ KIN) opened at $7.35 on Thursday. Kindred Biosciences, Inc. has a 52-week low of $3.90 and a 52-week high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. equities analysts anticipate that Kindred Biosciences, Inc. will post -1.18 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/23/goldman-sachs-group-inc-sells-6826-shares-of-kindred-biosciences-inc-kin.html.

Kindred Biosciences Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.